Antagonistic anti-CTLA4 antibodies have been extensively tested in cancer models as a strategy to activate anti-tumor immunity, and CTLA4 was the first immune checkpoint targeted in the clinic for cancer therapy. Here, CTLA4 is linked to cancer.